Rising Pharmaceuticals, Inc. FDA Inspection Record
Rising Pharmaceuticals, Inc. is an FDA-inspected facility (FEI 3004813192) located in Saddle Brook, NJ, US. RegDataLab tracks 3 FDA inspections at this facility.
What FDA found at this site
- Latest inspection
- Jan 28, 2019: Voluntary Action Indicated (VAI)
- Inspections on record
- 3 (1 VAI, 2 NAI)
- Last OAI inspection
- None on record
- Warning letters
- None matched to this FEI. Many letters do not state an FEI: search warning letters by company name
- Recalls as the recalling firm
- 3, latest Nov 15, 2019
- Import refusals
- 1
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Jan 28, 2019 | Voluntary Action Indicated (VAI) | Late submission of quarterly safety reports (21 CFR 314.80(c)(2)) |
| Jan 16, 2019 | No Action Indicated (NAI) | No citations listed |
| Sep 16, 2013 | No Action Indicated (NAI) | Specifications - labels, packaging (21 CFR 111.70(d)) Specifications - identity, purity, strength, composition (21 CFR 111.70(e)) Component - certificate of analysis (21 CFR 111.75(a)(2)(ii)(B)) |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Nov 15, 2019 | Class III | D-1367-2020 | Timolol Maleate USP, 0.5%, 5 mL, Sterile Opthalmic Solution, Rx Only, For Topical… and 1 more product Labeling: Label mix-up: A case of Timolol Maleate Sterile Ophthalmic solution USP 0.25%, 5ml, had the outer carton for Timolol Maleate… |
| Mar 7, 2019 | Class II | D-1052-2019 | Valsartan Tablets 40 mg USP, 30 tablet bottles, Rx, Only, Distributed by: Acetris Health… and 3 more products CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products |
| Jul 7, 2005 | Class III | D-441-5 | Renaphro Softgels, Each softgel contains: Vitamin C 100mg, Folic Acid 1mg, Niacinamide… Subpotent; calcium pantothenate |
FDA record score
3 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
2 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Inspection classified VAI | Jan 28, 2019 | 6 x 0.25 | 1.5 |
| Class II recall D-1052-2019, this FEI as the recalling firm | Mar 7, 2019 | 4 x 0.25 | 1 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Inspection citations | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 16, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 16, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 13, 2026 | Newest record Nov 12, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Rising Pharmaceuticals, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Rising Pharmaceuticals, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Rising Pharmaceuticals, Inc.
- Location
- Saddle Brook, NJ (US)
- Source
- inspections